<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<REGINFO_RIN_DATA xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" RUN_DATE="2026-04-10-04:00" xsi:noNamespaceSchemaLocation="https://www.reginfo.gov/public/xml/REGINFO_XML_Ver10262011.xsd">
    <RIN_INFO>
        <RIN>0910-AI21</RIN>
        <PUBLICATION>
            <PUBLICATION_ID>202210</PUBLICATION_ID>
            <PUBLICATION_TITLE>The Regulatory Plan and the Unified Agenda of Federal Regulatory and Deregulatory Actions</PUBLICATION_TITLE>
        </PUBLICATION>
        <AGENCY>
            <CODE>0910</CODE>
            <NAME>Food and Drug Administration</NAME>
            <ACRONYM>FDA</ACRONYM>
        </AGENCY>
        <PARENT_AGENCY>
            <CODE>0900</CODE>
            <NAME>Department of Health and Human Services</NAME>
            <ACRONYM>HHS</ACRONYM>
        </PARENT_AGENCY>
        <RULE_TITLE>Medical Devices; Ear, Nose and Throat Devices; Establishing Over-the-Counter Hearing Aids</RULE_TITLE>
        <ABSTRACT><![CDATA[<!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>FDA is establishing an over-the-counter category of hearing aids to promote the availability of additional kinds of devices that address perceived mild to moderate&nbsp;hearing loss. FDA is also making related amendments to the current hearing aid regulations, the regulations codifying FDA decisions on State applications for exemption from preemption, and the hearing aid classification regulations.&nbsp;</p>
</body>
</html>]]></ABSTRACT>
        <PRIORITY_CATEGORY>Economically Significant</PRIORITY_CATEGORY>
        <RIN_STATUS>Previously Published in The Unified Agenda</RIN_STATUS>
        <RULE_STAGE>Completed Actions</RULE_STAGE>
        <MAJOR>Yes</MAJOR>
        <UNFUNDED_MANDATE_LIST>
            <UNFUNDED_MANDATE>Private Sector</UNFUNDED_MANDATE>
        </UNFUNDED_MANDATE_LIST>
        <CFR_LIST>
            <CFR>21 CFR 800</CFR>
            <CFR>21 CFR 801</CFR>
            <CFR>21 CFR 808</CFR>
            <CFR>21 CFR 874</CFR>
        </CFR_LIST>
        <LEGAL_AUTHORITY_LIST>
            <LEGAL_AUTHORITY>21 U.S.C. 321</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 331 to 334</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 351 and 352</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 360</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 360c to 360e</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>Pub. L. 115-52, 131 Stat. 1065-67</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 360i to 360k</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 360l</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 371</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 374</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 381</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>...</LEGAL_AUTHORITY>
        </LEGAL_AUTHORITY_LIST>
        <LEGAL_DLINE_LIST>
            <LEGAL_DLINE_INFO>
                <DLINE_TYPE>Statutory</DLINE_TYPE>
                <DLINE_ACTION_STAGE>NPRM</DLINE_ACTION_STAGE>
                <DLINE_DATE>08/18/2020</DLINE_DATE>
                <DLINE_DESC></DLINE_DESC>
            </LEGAL_DLINE_INFO>
        </LEGAL_DLINE_LIST>
        <RPLAN_ENTRY>No</RPLAN_ENTRY>
        <TIMETABLE_LIST>
            <TIMETABLE>
                <TTBL_ACTION>NPRM</TTBL_ACTION>
                <TTBL_DATE>10/20/2021</TTBL_DATE>
                <FR_CITATION>86 FR  58150</FR_CITATION>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>NPRM Comment Period End</TTBL_ACTION>
                <TTBL_DATE>01/18/2022</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Final Rule</TTBL_ACTION>
                <TTBL_DATE>08/17/2022</TTBL_DATE>
                <FR_CITATION>87 FR 50698</FR_CITATION>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Final Rule Effective</TTBL_ACTION>
                <TTBL_DATE>10/17/2022</TTBL_DATE>
            </TIMETABLE>
        </TIMETABLE_LIST>
        <RFA_REQUIRED>No</RFA_REQUIRED>
        <SMALL_ENTITY_LIST>
            <SMALL_ENTITY>No</SMALL_ENTITY>
        </SMALL_ENTITY_LIST>
        <GOVT_LEVEL_LIST>
            <GOVT_LEVEL>State</GOVT_LEVEL>
        </GOVT_LEVEL_LIST>
        <FEDERALISM>Yes</FEDERALISM>
        <PRINT_PAPER>No</PRINT_PAPER>
        <INTERNATIONAL_INTEREST>No</INTERNATIONAL_INTEREST>
        <AGENCY_CONTACT_LIST>
            <CONTACT>
                <FIRST_NAME>Ian</FIRST_NAME>
                <LAST_NAME>Ostermiller</LAST_NAME>
                <TITLE>Regulatory Counsel, Center for Devices and Radiological Health</TITLE>
                <AGENCY>
                    <CODE>0910</CODE>
                    <NAME>Food and Drug Administration</NAME>
                    <ACRONYM>FDA</ACRONYM>
                </AGENCY>
                <PHONE>301 796-5678</PHONE>
                <EMAIL>ian.ostermiller@fda.hhs.gov</EMAIL>
                <MAILING_ADDRESS>
                    <STREET_ADDRESS>10903 New Hampshire Avenue, WO 66, Room 5454,</STREET_ADDRESS>
                    <CITY>Silver Spring</CITY>
                    <STATE>MD</STATE>
                    <ZIP>20993</ZIP>
                </MAILING_ADDRESS>
            </CONTACT>
        </AGENCY_CONTACT_LIST>
    </RIN_INFO>
</REGINFO_RIN_DATA>
